The Impact of Body Mass Index Upon the Efficacy of Adalimumab in Hidradenitis Suppurativa

Elevated BMI in Hidradenitis Suppurativa is associated with decreased response to Adalimumab therapy. BMI is proposed to segregate distinct disease subtypes. It remains unresolved whether a threshold BMI exists above which increased dosages may provide clinical benefit. Individual patient data from...

Descripción completa

Detalles Bibliográficos
Autores principales: Frew, John W., Singh, N., Jiang, C. S., Vaughan, R., Krueger, J. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257943/
https://www.ncbi.nlm.nih.gov/pubmed/34239882
http://dx.doi.org/10.3389/fmed.2021.603281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257943/
https://www.ncbi.nlm.nih.gov/pubmed/34239882
http://dx.doi.org/10.3389/fmed.2021.603281

Ejemplares similares